Loading
MAJIC-PV, a UK academic trial, found that ruxolitinib gave more complete responses than best available therapy and, for the first time, that a complete response went with fewer clots and progressions.
MAJIC-PV randomised 180 patients with PV resistant to or intolerant of hydroxyurea to ruxolitinib or best available therapy. Complete response within a year, the primary endpoint, was reached by 43 percent on ruxolitinib versus 26 percent on best available therapy; complete responders had better event-free survival (thrombosis, haemorrhage, transformation or death), and the JAK2 V617F allele burden fell more on ruxolitinib (Harrison and colleagues, Journal of Clinical Oncology 2023). Registered as ISRCTN61925716.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
180 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Complete response within 1 yearprimary | Ruxolitinib | 93 | 43% | - | - | - |
| Best available therapy | 87 | 26% |
Shares Polycythaemia vera (PV), Ruxolitinib, Small-molecule kinase inhibitors and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV), Ruxolitinib, Small-molecule kinase inhibitors and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV), Ruxolitinib and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV), Ruxolitinib and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV), Ruxolitinib and the tags polycythaemia-vera, mpn.
Shares Clearing the JAK2 clone in polycythaemia vera: interferon plus mutant-selective inhibitors as a route to treatment-free remission, Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.